The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 38 | 24.8x | 20.1x | Near average | |
Growth | 84 | 28.6% | 5.6% | Above average | |
Quality | 84 | 23.0% | 7.6% | Above average | |
Safety | 84 | -0.9x | 0.4x | Above average | |
Capital Return | 30 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Neurocrine Biosciences, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Neurocrine Biosciences, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
NBIX has shown notable stability in its average price target at 184.38 dollars, despite a significant increase in the number of analysts participating in coverage from 6 to 13 analysts over the past thirty days. This consistency in consensus despite the entry of new opinions indicates strong conviction among research institutions regarding the stock's current fair value, with a positive price gap (Upside) compared to the current price of 156.7 dollars.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.